NCT03314935: A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors

NCT03314935
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1|Ph+ase 2
Drug Category: Misc Inhibitor, Immunotherapy, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with known active CNS metastases and/or carcinomatous meningitis
https://ClinicalTrials.gov/show/NCT03314935

Comments are closed.

Up ↑